How should meropenem be dosed in end‑stage renal disease (ESRD) patients—specifically for those on intermittent hemodialysis, continuous renal replacement therapy, and those not receiving dialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Meropenem Dosing in ESRD

For ESRD patients, meropenem dosing must be reduced to half the standard dose with extended intervals: 500 mg every 24 hours for complicated skin/soft tissue infections and 500 mg every 24 hours for intra-abdominal infections when creatinine clearance is <10 mL/min. 1

Patients NOT on Dialysis (CrCl <10 mL/min)

The FDA-approved dosing for anuric ESRD patients is straightforward:

  • Complicated skin/soft tissue infections: 250 mg every 24 hours (half of the 500 mg standard dose)
  • Intra-abdominal infections: 500 mg every 24 hours (half of the 1 gram standard dose)

The elimination half-life extends dramatically from ~1 hour in normal renal function to 7-13.7 hours in anuric patients 2, 3. This prolonged half-life necessitates the 24-hour dosing interval to prevent drug accumulation.

Patients on Intermittent Hemodialysis (IHD)

Administer meropenem AFTER each hemodialysis session 1, 3. The standard approach is:

  • Dose: 500 mg (for standard infections) to 1 gram (for severe infections or P. aeruginosa)
  • Timing: Immediately post-dialysis
  • Frequency: After each dialysis session (typically 3 times weekly)

Hemodialysis removes approximately 50% of meropenem, reducing the elimination half-life from 7 hours to 2.9 hours during the dialysis session 2, 3. Post-dialysis dosing prevents premature drug removal and ensures adequate concentrations between sessions.

Critical caveat: The FDA label states "inadequate information" exists for hemodialysis dosing 1, but research consistently supports post-dialysis administration at standard or half-standard doses depending on infection severity 2, 3, 4.

Patients on Continuous Renal Replacement Therapy (CRRT)

For CRRT, use 500 mg to 1 gram every 8-12 hours as a 3-hour infusion 5, 6, 7, 8, 9. The specific regimen depends on:

Key Variables Affecting Dosing:

  • Residual diuresis: Patients with preserved urine output (>100 mL/24h) require higher doses or more frequent administration 5
  • CRRT intensity: Higher effluent rates (>35 mL/kg/h) increase meropenem clearance 9
  • Target pathogen MIC: For organisms with MIC ≤2 mg/L, 500 mg q8h suffices; for MIC 2-4 mg/L, increase to 500 mg q6h or 1 gram q8h 5, 8

Recommended CRRT Regimens:

For oligoanuric patients (minimal residual diuresis):

  • Standard infections (MIC ≤2 mg/L): 500 mg every 8 hours as 30-minute bolus 5
  • Resistant organisms (MIC 2-4 mg/L): 500 mg every 6 hours as 30-minute bolus 5

For patients with preserved diuresis (>500 mL/24h):

  • Standard infections: 500 mg every 8 hours as 3-hour infusion 5, 8
  • Resistant organisms: 1 gram every 8 hours as 3-hour infusion 6, 8

CRRT removes 13-53% of meropenem depending on modality (CVVHF removes 25-50%, CVVHDF removes 13-53%) 2. Continuous venovenous hemodialysis (CVVHD) and continuous venovenous hemofiltration (CVVHF) have similar clearance rates, allowing similar dosing regimens 9.

Extended Infusion vs. Bolus in CRRT

Extended infusions (3 hours) are superior to bolus dosing for achieving 100% fT>MIC, particularly for organisms with higher MICs 5, 7, 8. Continuous infusion (2 g/24h after 500 mg loading dose) maintains steady-state concentrations of 18.6 mg/L, providing consistent coverage 7, 4.

Pharmacokinetic/Pharmacodynamic Targets

The therapeutic goal is maintaining free drug concentrations above the MIC for 40-100% of the dosing interval (40-100% fT>MIC) 5, 6, 9. For critically ill patients:

  • Minimum target: 40% fT>MIC for clinical cure
  • Optimal target: 100% fT>MIC for maximal bacterial killing
  • Enhanced target: 100% fT>4×MIC for immunocompromised or severe sepsis 8, 9

Common Pitfalls

  1. Underdosing in CRRT: The FDA label provides no CRRT guidance 1, leading clinicians to use overly conservative dosing. Research demonstrates that 500 mg-1 gram q8h is safe and necessary 5, 6, 8.

  2. Ignoring residual renal function: Patients with preserved diuresis (even 100-500 mL/24h) have significantly higher meropenem clearance and require dose adjustments 5.

  3. Timing errors in IHD: Administering meropenem before dialysis results in immediate drug removal and therapeutic failure 3.

  4. Nephrotoxicity concerns: While trough concentrations ≥45 mg/L carry nephrotoxicity risk 8, this is rarely achieved with recommended ESRD dosing. The excellent tolerability profile means underdosing is a greater risk than toxicity 2.

  5. Pediatric extrapolation: Meropenem clearance in children with ESRD differs from adults. The FDA provides no pediatric ESRD dosing 1, and limited data suggests weight-based dosing with therapeutic drug monitoring 10.

Monitoring Recommendations

  • Therapeutic drug monitoring: Consider measuring trough concentrations in CRRT patients, targeting 8-20 mg/L for MIC ≤2 mg/L organisms 5, 8
  • Clinical response: Assess at 48-72 hours; lack of improvement suggests inadequate dosing or resistant organism
  • Residual renal function: Monitor urine output in CRRT patients to guide dose adjustments 5

References

Related Questions

What is the appropriate meropenem dose and schedule for treating typhoid fever, and how should it be adjusted in renal impairment?
What meropenem dose and treatment duration should be used for a Klebsiella infection in an adult, including adjustments for impaired renal function?
What is the recommended dosing of Meropenem (Meropenem) for a patient undergoing Continuous Renal Replacement Therapy (CRRT) with impaired renal function?
What is the appropriate meropenem dose for a diabetic foot infection in a patient with a creatinine clearance of 54 mL/min?
In severe acute pancreatitis, when is meropenem indicated, what is the appropriate dosing regimen, and how should the dose be adjusted for renal impairment?
Is cerebral atrophy a risk factor for dementia or Alzheimer's disease?
How should a patient presenting with cough and a 5 mm ground‑glass opacity nodule be evaluated and managed?
Is a low-grade fever normal after adenoidectomy?
What level of SARS‑CoV‑2 spike‑protein antibodies is expected five years after COVID‑19 vaccination or infection?
When is clindamycin indicated for a lung infection in adults, and what is the appropriate dosing, duration, and monitoring?
What is the recommended cefazolin (Ancef) dosing and timing for surgical prophylaxis in an adult with an open fracture and normal renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.